Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study

Systemic Sclerosis

Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study

Rheumatology (Oxford)

Li Q, Wallace L, Patnaik P, Alves M, Gahlemann M, Kohlbrenner V, Raabe C, Wang JR, Garry EM

doi: 10.1093/rheumatology/keaa547

Further Publications Rheumatology

Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study

Semin Arthritis Rheum

Vandecasteele E, Melsens K, Vanhaecke A, Blockmans D, Bonroy C, Carton C, Deschepper E, De Keyser F, Houssiau F, Piette Y, Vanthuyne M, Verbeke K, Westhovens R, Wuyts WA, De Langhe E, Brusselle G, Smith V

doi: 10.1016/j.semarthrit.2021.07.018

Psoriatic Arthritis

Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study

Arthritis Res Ther.

Queiro R, Cañete JD, Montoro M, Gómez S, Cábez A, MAAPS study group.

doi: 10.1186/s13075-020-02168-1.

EULAR ^® 2019

Systemic Sclerosis-Associated Interstitial Lung Disease

Distler et al. 2019. Nintedanib reduced decline in forced vital capacity across subgroups of patients with systemic sclerosis-associated interstitial lung disease: Data from the SENSCIS trial. Oral presentation presented at: EULAR 2019 Congress; 12–15 June 2019; Madrid, Spain.

COMMENTED

Systemic Sclerosis

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)

★ 3 Recommended and commented by Dr Heino Prillwitz, Faculty Member

Arthritis Res Ther.

Pan Z, Marra AM, Benjamin N, Eichstaedt CA, Blank N, Bossone E, Cittadini A, Coghlan G, Denton CP, Distler O, Egenlauf B, Fischer C, Harutyunova S, Xanthouli P, Lorenz HM, Grünig E

doi: 10.1186/s13075-019-1981-0.

Melanoma and Skin Cancer

A prospective cohort study of Condensed low dose total skin electron beam therapy for mycosis fungoides: reduction of disease burden and improvement in quality of life

J Am Acad Dermatol.

Song A, Gochoco A, Zhan T, Sahu J, Alpdogan O, Porcu P, Nikbakht N, Shi W

doi: 10.1016/j.jaad.2020.01.046.

Psoriatic Arthritis

Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study

Rheumatology (Oxford).

Charlton R, Green A, Shaddick G, Snowball J, Nightingale A, Tillett W, Smith C, McHugh N; PROMPT study group

doi: 10.1093/rheumatology/key286.

Systemic Sclerosis

The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort

Swiss Med Wkly

Hernández J, Jordan S, Dobrota R, Iudici M, Hasler P, Ribi C, Villiger P, Vlachoyiannopoulos P, Vacca A, Garzanova L, Giollo A, Rosato E, Kötter I, Carreira PE, Doria A, Henes J, Müller-Ladner U, Smith V, Distler J, Gabrielli A, Hoffman-Vold AM, Walker U, Distler O, The Eustar Collaborators

doi: 10.4414/smw.2021.20528

Further Publications Rheumatology

Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression

Respirology

Stock CJW, Hoyles RK, Daccord C, Kokosi M, Visca D, De Lauretis A, Alfieri V, Kouranos V, Margaritopoulos G, George PM, Molyneaux PL, Chua F, Maher TM, Abraham DJ, Ong V, Donovan J, Sestini P, Denton CP, Wells AU, Renzoni EA

doi: 10.1111/resp.13988

Related content

Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study

Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study

Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study

Systemic Sclerosis-Associated Interstitial Lung Disease

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)

A prospective cohort study of Condensed low dose total skin electron beam therapy for mycosis fungoides: reduction of disease burden and improvement in quality of life

Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study

The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort

Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression